BioLife Solutions (NASDAQ:BLFS) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Valuation & Earnings
This table compares BioLife Solutions and Stereotaxis' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
BioLife Solutions | $27.37 million | 38.45 | $-1,660,000.00 | $0.08 | 393.88 |
Stereotaxis | $28.90 million | 19.69 | $-4,590,000.00 | ($0.10) | -76.80 |
BioLife Solutions has higher earnings, but lower revenue than Stereotaxis. Stereotaxis is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
BioLife Solutions has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.
Profitability
This table compares BioLife Solutions and Stereotaxis' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
BioLife Solutions | 12.67% | 0.53% | 0.43% |
Stereotaxis | -24.54% | -22.78% | -13.15% |
Analyst Recommendations
This is a summary of current ratings for BioLife Solutions and Stereotaxis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
BioLife Solutions | 0 | 1 | 9 | 0 | 2.90 |
Stereotaxis | 0 | 0 | 2 | 0 | 3.00 |
BioLife Solutions currently has a consensus target price of $46.6667, suggesting a potential upside of 48.10%. Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given BioLife Solutions' higher probable upside, research analysts clearly believe BioLife Solutions is more favorable than Stereotaxis.
Summary
BioLife Solutions beats Stereotaxis on 10 of the 14 factors compared between the two stocks.